A controlled study to improve sputum conversion rate of current short course chemotherapy using immunomodulator containing mycobacterium w had been shown earlier. The same randomised study was continued further till the end of therapy. At the end of the intensive phase, sputum conversion rate in category II was 75.51% in mycobacterium w (MW) group as compared to 51.85% in the control group. The cure rate in category II was 97.96% and 77.77% in MW and control groups, respectively. Treatment failure in category 11 was 2.04% and 22.22% in MW and control groups respectively. The therapy was well tolerated.